Telix Pharmaceuticals Q4 Revenue Climbs

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RLS third-party.

For the three-month period to December 31, 2025, the company posted revenue of $208 million, higher than $142 million in the same period last year.

Revenue from the Precision Medicine segment moved up to $161 million from $139 million a year ago. RLS third-party revenue stood at $45 million, compared with $00.00 million last year.

TLX was down by 1.03% at $7.68 in the pre-market trade on the Nasdaq.